Cognition Therapeutics Inc. has filed a prospectus with the U.S. Securities and Exchange Commission (SEC) as part of a registered direct offering of common stock. The company, focused on developing treatments for neurodegenerative disorders, closed the offering of 14,700,000 shares at $2.05 per share, raising approximately $30 million in gross proceeds. This capital is intended to support the Phase 3 development of their drug, zervimesine. Titan Partners Group, a division of American Capital Partners, served as the sole placement agent. The shares were offered under a shelf registration statement that became effective on January 3, 2023. The prospectus is accessible through the SEC's website or by contacting Titan Partners Group directly.